Rituximab: perspective on single agent experience, and future directions in combination trials

被引：53

作者：

McLaughlin, P ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2001年 / 40卷 / 01期

关键词：

rituximab; monoclonal antibody therapy; CD20; B-cell lymphoma; malignant lymphoma;

D O I：

10.1016/S1040-8428(01)00130-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The chimeric anti-CD20 antibody rituximab is the first monoclonal antibody to gain regulatory approval for the treatment Of any malignancy. As such, its development represents a major milestone in cancer therapy. It is an effective single agent for patients with CD20-positive B-cell malignancies, using a well-tolerated and brief (weekly x 4) schedule that has become the accepted standard. Since this weekly x 4 schedule is not a maximum tolerated dose. additional research is being done on different doses and schedules of rituximab. Researchers are also exploring the use of rituximab in conjunction with cytokines or chemotherapy. Further developments in the use of rituximab and other targeted therapy approaches can be expected as we learn more about the mechanisms of action of. and resistance to. rituximab. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：3 / 16

页数：14

共 129 条

[31] A new era for radiolabeled antibodies in cancer? [J].

DeNardo, SJ ;

Kroger, LA ;

DeNardo, GL .

CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (05) :563-569

[32]

DILLMAN RO, 1990, ANTIBODY IMMUNOCONJ, V3, P1

[33] MOLECULAR-CLONING OF THE HUMAN B-CELL CD20 RECEPTOR PREDICTS A HYDROPHOBIC PROTEIN WITH MULTIPLE TRANSMEMBRANE DOMAINS [J].

EINFELD, DA ;

BROWN, JP ;

VALENTINE, MA ;

CLARK, EA ;

LEDBETTER, JA .

EMBO JOURNAL, 1988, 7 (03) :711-717

[34]

Emmanouilides C, 1999, BLOOD, V94, p92A

[35]

Flieger D, 1999, EUR J CANCER, V35, pS57

[36]

Flinn IW, 1998, BLOOD, V92, p648A

[37]

FOON KA, 1984, BLOOD, V64, P1085

[38] European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma [J].

Foran, JM ;

Rohatiner, AZS ;

Cunningham, D ;

Popescu, RA ;

Solal-Celigny, P ;

Ghielmini, M ;

Coiffier, B ;

Johnson, PWM ;

Gisselbrecht, C ;

Reyes, F ;

Radford, JA ;

Bessell, EM ;

Souleau, B ;

Benzohra, A ;

Lister, TA .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) :317-324

[39] Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells [J].

Ghetie, MA ;

Podar, EM ;

Ilgen, A ;

Gordon, BE ;

Uhr, JW ;

Vitetta, ES .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (14) :7509-7514

[40] The high-dose sequential (Milan) chemotherapy PBSC transplantation regimen for patients with lymphoma is not cardiotoxic [J].

Ghielmini, M ;

Zappa, F ;

Menafoglio, A ;

Caoduro, L ;

Pampallona, S ;

Gallino, A .

ANNALS OF ONCOLOGY, 1999, 10 (05) :533-537

← 1 2 3 4 5 6 7 8 9 10 →